231 related articles for article (PubMed ID: 6821229)
1. How to escape immune surveillance?
Zinkernagel RM
Springer Semin Immunopathol; 1982; 5(1):107-12. PubMed ID: 6821229
[No Abstract] [Full Text] [Related]
2. [Genetics of the immune response].
Tsoneva M
Vutr Boles; 1983; 22(5):1-13. PubMed ID: 6424336
[No Abstract] [Full Text] [Related]
3. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
4. [Antigenic signal to immunocompetent cells].
Marx A
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1985; 30(1):1-12. PubMed ID: 3159067
[No Abstract] [Full Text] [Related]
5. Mhc restriction and Ir genes.
Klein J; Nagy ZA
Adv Cancer Res; 1982; 37():233-317. PubMed ID: 6222631
[No Abstract] [Full Text] [Related]
6. The cellular and humoral basis of the immune response.
Yunis E
Semin Arthritis Rheum; 1983 Aug; 13(1 Suppl 1):89-93. PubMed ID: 6414085
[TBL] [Abstract][Full Text] [Related]
7. HLA and cancer.
Garrido F
Tissue Antigens; 1996 May; 47(5):361-3. PubMed ID: 8795135
[No Abstract] [Full Text] [Related]
8. An introduction to tumour immunology.
Keith J
Mater Med Pol; 1984; 16(1):54-64. PubMed ID: 6394909
[No Abstract] [Full Text] [Related]
9. Immunological help at last.
Howard JC
Nature; 1985 Apr 11-17; 314(6011):494-5. PubMed ID: 3157868
[No Abstract] [Full Text] [Related]
10. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
[TBL] [Abstract][Full Text] [Related]
11. [The immune system - how does anti-tumor immunity arise ?].
Sankawa Y
Oncol Res Treat; 2014; 37 Suppl 4():2-5. PubMed ID: 25301189
[No Abstract] [Full Text] [Related]
12. Experiments and speculation on antiviral specificity of T and B cells.
Zinkernagel RM; Rosenthal KL
Immunol Rev; 1981; 58():131-55. PubMed ID: 6171502
[No Abstract] [Full Text] [Related]
13. Immune response to autologous human melanoma: implication of class I and II MHC products.
Fossati G; Anichini A; Taramelli D; Balsari A; Gambacorti-Passerini C; Kirkwood JM; Parmiani G
Biochim Biophys Acta; 1986 Dec; 865(3):235-51. PubMed ID: 3539196
[No Abstract] [Full Text] [Related]
14. Immunoregulation.
Taurog JD
Ann Neurol; 1981; 9 Suppl():107-16. PubMed ID: 6784666
[TBL] [Abstract][Full Text] [Related]
15. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors.
Ward PL; Schreiber H
Semin Cancer Biol; 1991 Oct; 2(5):321-8. PubMed ID: 1837738
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune reactions to human tumors.
Perlmann P; Troye M; Pape GR
Cancer; 1977 Jul; 40(1 Suppl):448-57. PubMed ID: 69485
[No Abstract] [Full Text] [Related]
17. Autoimmunity and HLA.
Carpenter CB
J Clin Immunol; 1982 Jul; 2(3):157-65. PubMed ID: 6811606
[No Abstract] [Full Text] [Related]
18. The suppressor-cell network in cancer (first of two parts).
Broder S; Waldmann TA
N Engl J Med; 1978 Dec; 299(23):1281-4. PubMed ID: 101844
[No Abstract] [Full Text] [Related]
19. [Mechanism of immune response].
Gülmezoğlu E
Mikrobiyol Bul; 1982 Jul; 16(3):217-23. PubMed ID: 6820118
[TBL] [Abstract][Full Text] [Related]
20. Using Autoimmunity To Inform Tumor Immunity.
Sherman LA
J Immunol; 2015 Dec; 195(11):5091-5. PubMed ID: 26589742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
